Durvalumab
J2031
Phase 2 small_molecule completed
Quick answer
Durvalumab for Unresectable Intrahepatic Cholangiocarcinoma is a Phase 2 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Unresectable Intrahepatic Cholangiocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed